Samsung Biologics' Big Gains and Ambitious Moves in 2026
A Robust Third Quarter Samsung Biologics is making some serious noise in the biopharma sector with its latest Q3 2026 financial results. We're talking about KRW 1,490 billion in revenue, an uptick that screams growth, backed by an operating profit of KRW 640 billion. What's fueling this engine? Their relentless plant expansion and a pivotal step into the U.S. market....
Continue Reading